Format
Items per page
Sort by

Send to:

Choose Destination

Results: 9

Cited In for PubMed (Select 20406939)

1.

A late, solitary brain metastasis of epithelial ovarian carcinoma.

Longo R, Platini C, Eid N, Elias-Matta C, Buda T, 'Nguyen D, Quétin P.

BMC Cancer. 2014 Jul 28;14:543. doi: 10.1186/1471-2407-14-543.

2.

Differences in clinical presentation of non-small cell lung cancer in never-smokers versus smokers.

Lee JY, Na II, Jang SH, Hwang YI, Choe du H, Kim CH, Baek H.

J Thorac Dis. 2013 Dec;5(6):758-63. doi: 10.3978/j.issn.2072-1439.2013.11.24.

3.

Update on first-line treatment of advanced ovarian carcinoma.

Kemp Z, Ledermann J.

Int J Womens Health. 2013;5:45-51. doi: 10.2147/IJWH.S30231. Epub 2013 Jan 25.

4.

Brain metastasis as an initial manifestation of ovarian carcinoma: a case report.

Tuncer ZS, Boyraz G, Yazıcıoğlu A, Selcuk I, Yücel SÖ.

Case Rep Med. 2012;2012:735026. doi: 10.1155/2012/735026. Epub 2012 Dec 22. Retraction in: Case Reports In Medicine. Case Rep Med. 2013;2013:467654.

5.

Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.

Liu G, Yang D, Sun Y, Shmulevich I, Xue F, Sood AK, Zhang W.

Pharmacogenomics. 2012 Oct;13(13):1523-35. doi: 10.2217/pgs.12.137. Review.

6.

BRCAness: finding the Achilles heel in ovarian cancer.

Rigakos G, Razis E.

Oncologist. 2012;17(7):956-62. doi: 10.1634/theoncologist.2012-0028. Epub 2012 Jun 6. Review.

7.

Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma.

Hyman DM, Long KC, Tanner EJ, Grisham RN, Arnold AG, Bhatia J, Phillips MF, Spriggs DR, Soslow RA, Kauff ND, Levine DA.

Gynecol Oncol. 2012 Aug;126(2):224-8. doi: 10.1016/j.ygyno.2012.05.001. Epub 2012 May 8.

8.

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.

Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, Lambrechts D, Despierre E, Barrowdale D, McGuffog L, Healey S, Easton DF, Sinilnikova O, Benítez J, García MJ, Neuhausen S, Gail MH, Hartge P, Peock S, Frost D, Evans DG, Eeles R, Godwin AK, Daly MB, Kwong A, Ma ES, Lázaro C, Blanco I, Montagna M, D'Andrea E, Nicoletto MO, Johnatty SE, Kjær SK, Jensen A, Høgdall E, Goode EL, Fridley BL, Loud JT, Greene MH, Mai PL, Chetrit A, Lubin F, Hirsh-Yechezkel G, Glendon G, Andrulis IL, Toland AE, Senter L, Gore ME, Gourley C, Michie CO, Song H, Tyrer J, Whittemore AS, McGuire V, Sieh W, Kristoffersson U, Olsson H, Borg Å, Levine DA, Steele L, Beattie MS, Chan S, Nussbaum RL, Moysich KB, Gross J, Cass I, Walsh C, Li AJ, Leuchter R, Gordon O, Garcia-Closas M, Gayther SA, Chanock SJ, Antoniou AC, Pharoah PD; EMBRACE; kConFab Investigators; Cancer Genome Atlas Research Network.

JAMA. 2012 Jan 25;307(4):382-90. doi: 10.1001/jama.2012.20.

9.

A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer.

Adams SF, Marsh EB, Elmasri W, Halberstadt S, Vandecker S, Sammel MD, Bradbury AR, Daly M, Karlan B, Rubin SC.

Gynecol Oncol. 2011 Dec;123(3):486-91. doi: 10.1016/j.ygyno.2011.08.032. Epub 2011 Sep 25.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk